In the Claims:

Please cancel claims 1-14 and add new claims 15-36, as follows:

- 15. A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal in a suitable regimen an effective amount of an insulin and an effective amount of a glucagon-like peptide 1(7-36) amide agonist.
- 16. A method according to claim 15 wherein said mammal is human.
- 17. A method according to claim 16 wherein said insulin and said peptide are administered to the human at a selected time prior to ingestion of a meal.
- 18. A method according to any of claims 15-17 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-37).
- 19. A method according to any of claims 15-17 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-36) amide.
- 20. A method according to any of claims 15-17 wherein said glucagon-like peptide 1(7-36) amide agonist is administered subcutaneously.

- 21. A method according to claim 18 wherein said glucagon-like peptide 1(7-37) is administered subcutaneously.
- 22. A method according to claim 19 wherein said glucagon-like peptide 1(7-36) amide is administered subcutaneously.
- 23. A method of treating Type I diabetes mellitus in a mammal comprising administering to said mammal in a suitable regimen an effective amount of a glucagon-like peptide 1(7-36) amide agonist.

24. A method according to claim 23 wherein said mammal

- 25. A method according to claim 24 wherein said glucagon-like peptide 1(7-36) amide agonist is administered to the human at a selected time prior to ingestion of a meal.
- 26. A method according to any of claims 23-25 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-37).
- 27. A method according to any of claims 23-25 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-36) amide.

- 28. A method according to any of claims 23-25 wherein said glucagon-like peptide 1(7-36) amide agonist is administered subcutaneously.
- 29. A method according to claim 26 wherein said glucagon-like peptide 1(7-37) is administered subcutaneously.
- 30. A method according to claim 27 wherein said glucagon-like peptide 1 (7-36) amide is administered subcutaneously.
- 31. A pharmaceutical composition for the treatment of Type I diabetes mellitus comprising an amount of a glucagon-like peptide 1(7-36) amide agonist in association with a pharmaceutically acceptable carrier effective to treat said Type I diabetes mellitus.
- 32. A pharmaceutical composition according to claim 31 further comprising an effective amount of an insulin.
- 33. A pharmaceutical composition according to claim 31 or claim 32 wherein said glucagon-like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-37).
- 34. A pharmaceutical composition according to claim 31 or claim 32 wherein said glucagon like peptide 1(7-36) amide agonist is glucagon-like peptide 1(7-36) amide.

Patent 223/051

- 35. A pharmaceutical composition according to claim 31 or 32 wherein said pharmaceutically acceptable carrier is adapted for subcutaneous injection.
- 36. A pharmaceutical composition according to claim 33 wherein said pharmaceutically acceptable carrier is adapted for subcutaneous injection.

wherein said pharmaceutically acceptable carrier is adapted for subcutaneous injection.

In the Specification:

At page 3, line 23, defore "shows human pancreatic," please replace "Figure 1D" with --Figure 1C--.

REMARKS

Claims 1-14 are pending in the present application. In this Response, applicant is canceling these claims and adding new claims 15-37. Support for new claims 15-37 is found throughout the specification and claims as originally filed. Support for claim 15 is found, for example, in original claims 1, 4 and 13 and in page 4 of the specification. Support for claim 16 is found, for example, in original claims 2 and 13. Support for claim 17 is found, for example, in original claims 3 and 13. Support for claims 18 and 19 is found, for example, in original